PATRICK DEVAL L - 14 Jun 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role
Director
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
14 Jun 2022
Net transactions value
$0
Form type
4
Filing time
16 Jun 2022, 18:00:16 UTC
Previous filing
15 Jun 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Quoteable Key Fact

"PATRICK DEVAL L filed Form 4 for Global Blood Therapeutics, Inc. on 16 Jun 2022."

Quick Takeaways

  • This page summarizes PATRICK DEVAL L's Form 4 filing for Global Blood Therapeutics, Inc..
  • 4 reported transactions and 3 derivative rows are listed below.
  • Filing timestamp: 16 Jun 2022, 18:00.

What Changed

  • Previous filing in this sequence was filed on 15 Jun 2022.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +3,600 +66% 9,037 14 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -3,600 -100% $0.000000* 0 14 Jun 2022 Common Stock 3,600 Direct F1, F2
transaction GBT Stock Option (Right to Buy) Award $0 +5,600 $0.000000 5,600 14 Jun 2022 Common Stock 5,600 $22.30 Direct F3
transaction GBT Restricted Stock Units Award $0 +3,600 $0.000000 3,600 14 Jun 2022 Common Stock 3,600 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The RSUs vested in a single installment on June 14, 2022.
F3 The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
F4 The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).